
Medicare and Medicaid will not cover weight loss drugs, Trump administration decides
The Trump administration has decided against implementing a proposal for Medicare and Medicaid to cover
weight loss drugs
, the Centers for Medicare and Medicaid Services said
in a filing
published Friday by the agency.
A CMS spokesperson said the agency now believes that finalizing the proposal "is not appropriate at this time."
"CMS may consider future policy options for AOMs pending further review of both the potential benefits of these drugs including updated clinical indications, and relevant costs including fiscal impacts on stakeholders such as state Medicaid agencies," Catherine Howden, the spokesperson, said in an email.
Medicare already covers drugs that are also widely used for weight loss, like Ozempic and Mounjaro, when they are prescribed by doctors for other reasons like managing diabetes.
But under the statute governing Medicare and Medicaid, the federal government is generally banned from covering drugs "when used for weight loss."
Under the Biden administration, CMS had
proposed
to reinterpret this statute, bypassing the Congressional ban on coverage of weight loss drugs for obese, but not overweight, patients.
Since
obesity
is now widely agreed to be a disease, the Biden administration had said, treatment of that disease should be covered by Medicare's Part D prescription drug benefit.
They pointed to other situations when these kinds of drugs are allowed to be covered, like when weight change is caused by AIDS.
Expanding coverage of anti-obesity medications this way would also affect state Medicaid plans, officials said, since they are governed by the same law.
"CMS' revised interpretation would recognize obesity to be a chronic disease based on changes in medical consensus," the agency had said
last year
.
The proposal was expected to be costly for the federal government.
The Congressional Budget Office had
previously estimated
that expanding Medicare coverage to anti-obesity medications could add up to $35 billion over the next decade, even after factoring in expected savings from improved health of beneficiaries.
Medicaid programs would also have shouldered billions more in costs to cover the medications, Biden administration officials acknowledged, split between the federal government and states.
"States are also feeling substantial state budget pressure and we are doing our part to make sure patients, Medicaid enrollees all across the country can get access," Dan Tsai, the agency's top Medicaid official under the Biden administration, had told reporters.
Top advisers to Health and Human Services Secretary Robert F. Kennedy Jr., who now oversees CMS, among the nation's federal health agencies, had criticized the Biden-era move.
Healthcare entrepreneur Calley Means, now a special government employee under Kennedy,
had called it
a "betrayal of any American who cares about" the
Make America Healthy Again
movement's principles.
"Americans did NOT vote for mass injections in this election. They voted for a shift to ROOT CAUSE interventions and benefit flexibility," Means said in a
post on X
at the time.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
42 minutes ago
- Business Wire
Navitus Drug Trend Report: Keeping Costs Low for Plans and Members in an Era of Accelerating Inflation
MADISON, Wis.--(BUSINESS WIRE)-- Navitus, the nation's first transparent, pass-through pharmacy benefit manager (PBM), released its ninth annual Drug Trend Report today, revealing how commercial plan sponsors saved millions in prescription costs while maintaining high-quality member care. 30% of Navitus clients spent less in 2024 than in the previous year, while overall client book of business drug cost trend was managed to 7%. The data shows that medications such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are creating unprecedented financial pressure on plan sponsors as utilization for diabetes treatment increased 26% year-over-year. Overall health spending in the United States is nearly $4.9 trillion and projected to increase nearly 6% annually over the next decade. 1 A subset of this, prescription drug spending, was estimated to be $487 billion in 2024, an industry-wide 11.4% increase over the previous year, compared to 7% for Navitus clients. While the industry faces these escalating cost pressures, our latest Drug Trend Report highlights how Navitus continues to outperform industry trends and save clients money in this challenging environment, including companies such as Progressive Insurance. 'Navitus stands out for its commitment to transparency and managing to lowest net cost, which has significantly benefited Progressive and its members. From the outset, their 100% pass-through model has ensured that we receive the full value of manufacturer rebates and discounts, directly translating to reduced pharmacy costs,' said Heidi Minter, Data Analyst, Benefits & Design Services, Progressive Insurance. The Navitus Drug Trend Report revealed three critical trends influencing the broader industry: 1. 26% increase in GLP-1 RAs use for treatment of type 2 diabetes. While delivering significant clinical benefits, these medications are contributing substantially to pharmaceutical cost increases for benefit plans: Net trend in the diabetes category increased 8.5%, driven by growth in both the use of GLP-1 RAs, including Ozempic, Mounjaro and Trulicity, and a 16% increase in use of sodium-glucose cotransporter-2 inhibitors (SGLT-2s), including Farxiga and Jardiance. The prevalence and cost of GLP-1 RAs and SLGT-2s resulted in an overall unit cost increase of 3.0% for the diabetes category, in spite of the net cost decrease of more than 28% for insulin in 2024. 2. Biosimilars delivered $315 million in savings with a 60% reduction in Humira costs. Targeted immunomodulators (TIMs) treat a wide range of autoimmune disorders, from rheumatoid arthritis and psoriasis to inflammatory bowel diseases. The launch of Humira biosimilar alternatives in 2023 significantly changed the landscape of the category as these clinically-equivalent, much lower cost options were added to formulary. After adding biosimilars to formulary, Navitus took a decisive step to lower costs further by removing Humira from formulary in June 2024. This led to key results including: Over $315 million in upfront cost savings. 60% reduction in net costs per claim. 3. Specialty medication utilization increased 12%. Approximately 75% of new drug approvals have been for specialty or medical specialty agents, and that trend is expected to continue in the next two years. Key factors included: Oncology net trend increased more than 13%, driven by both higher utilization and unit cost: Utilization of newer breast cancer treatments (Kisqali, Verzenio) increased 20%, driving overall cost. In specialty dermatology, Dupixent (dupilumab) emerged as the most rapidly growing drug of 2024. The category saw a net trend increase of more than 45% and Dupixent represented 96% of category cost and utilization. While increased use of newer, more expensive agents like Kesimpta created upward pressure within the multiple sclerosis category, generics represented more than 50% of prescriptions filled at 10% of the cost. Expand 'Our annual Drug Trend Report confirms we were able to control year-over-year costs for commercial clients - both large and small - and deliver savings greater than the estimated industry averages,' said Sharon Faust, PharmD, MBA, CSP, Chief Pharmacy Officer, Navitus Health Solutions. 'Deploying generic-first strategies, facilitating adoption of new biosimilars, ensuring 100% pass-through of negotiated rebates and discounts, and supporting clinically appropriate prescribing, utilization and formulary management remain core to our focus.' Access the Navitus Drug Trend Report executive summary here: Methodology: The Navitus drug trend is calculated by comparing the net total cost per-member per-month (PMPM) for 2024 to that for 2023. Net cost PMPM represents full-year (Q1-Q4) data for total member copays and plan paid amounts minus manufacturer rebates and fees. This value is divided by the total number of members and by 12 months of the year. The data represents employer plan sponsors and health plans. In order to be included organizations must have been with Navitus for two full calendar years. * Due to varying coverage decisions by clients, GLP-1s for weight loss were not included in the Drug Trend Report, yet they still warrant thoughtful consideration and conversation in the overall picture of trend and future decisions. The DTR only represents prescriptions under the pharmacy benefit. 40% of Rx spend is through the medical benefit and warrants careful consideration by plans. Sources: About Navitus Navitus remains the nation's first transparent, pass-through pharmacy benefit manager (PBM). It uniquely brings clarity to drug pricing and takes costs out of the drug supply chain. Unlike traditional PBMs that generate profit by retaining an undisclosed portion of rebates and discounts negotiated with drug manufacturers and pharmacies, Navitus passes along the complete savings to clients, enabling them to make medication more affordable for their members. Navitus was established more than 20 years ago by Navitus Health Solutions, LLC, a pioneering pharmacy solutions company. The organization delivers a range of services through portfolio brands including Navitus, Lumicera, Archimedes. Owned by SSM Health and Costco, Navitus Health Solutions serves over 18 million lives across 800 clients including employers, unions, government plans, payors and health systems. For more information, please visit


San Francisco Chronicle
an hour ago
- San Francisco Chronicle
The Latest: Trump heads to Fort Bragg to celebrate 250th anniversary for US Army
President Donald Trump plans to speak at Fort Bragg on Tuesday to celebrate the 250th anniversary of the U.S. Army as he deploys the military in an attempt to quiet immigration protests in Los Angeles. Trump has promoted the Army's anniversary as a reason to hold a military parade in Washington, D.C., on Saturday, which is also his 79th birthday. Trump's Tuesday schedule, according to the White House 12:25 p.m. — Trump will travel to Fort Bragg, North Carolina 2:40 p.m. — Once he arrives, Trump will observe a military demonstration 4:00 p.m. — Trump will deliver remarks to service members, veterans and their families 6:00 p.m. — Trump will travel back to the White House Defense Secretary Pete Hegseth to face Congress for first time since Signal leaks He's expected to field sharp questions from members of Congress about his tumultuous start as Pentagon chief, including his sharing of sensitive military details over a Signal chat, in three separate Capitol Hill hearings beginning Tuesday. Lawmakers also have made it clear they're unhappy that Hegseth hasn't provided details on the administration's first proposed defense budget, which Trump has said would total $1 trillion, a significant increase over the current spending level of more than $800 billion. It will be lawmakers' first chance to ask Hegseth about a myriad of other controversial spending by the Pentagon, including plans to spend hundreds of millions of dollars on security upgrades to turn a Qatari jet into Air Force One and to pour as much as $45 million into a parade recently added to the Army's 250th birthday bash, which happens to coincide with Trump's birthday on Saturday. Kennedy on Monday removed every member of a scientific committee that advises the CDC on how to use vaccines and pledged to replace them with his own picks. Major physicians and public health groups criticized the move to oust all 17 members of the Advisory Committee on Immunization Practices. Kennedy, who was one of the nation's leading anti-vaccine activists before becoming the nation's top health official, has not said who he would appoint to the panel, but said it would convene in just two weeks in Atlanta. Although it's typically not viewed as a partisan board, the entire current roster of committee members were Biden appointees. Trump pushes ahead with his maximalist immigration campaign in face of LA protests Trump made no secret of his willingness to take a maximalist approach to enforcing immigration laws and keeping order as he campaigned to return to the White House. The fulfillment of that pledge is now on full display in Los Angeles. By overriding California's Gov. Gavin Newsom, Trump is already going beyond what he did to respond to Black Lives Matter protests in 2020, when he warned he could send troops to contain demonstrations that turned violent if governors in the states did not act to do so themselves. Trump said in September of that year that he 'can't call in the National Guard unless we're requested by a governor' and that 'we have to go by the laws.' But now, he's moving swiftly to test the bounds of his executive authority in order to deliver on his promise of mass deportations. What remains to be seen is whether Americans will stand by him once it's operationalized nationwide. For now, Trump is betting that they will. Trump heads to Fort Bragg while facing criticism for deploying military at Los Angeles protests Trump plans to speak at Fort Bragg on Tuesday to celebrate the 250th anniversary of the U.S. Army as he deploys the military in an attempt to quiet immigration protests in Los Angeles. Fort Bragg, located near Fayetteville, North Carolina, serves as headquarters for U.S. Army Special Operations Command. Highly trained units like the Green Berets and the Rangers are based there. Defense Secretary Pete Hegseth and Army Secretary Dan Driscoll will also be at Tuesday's event, along with service members, veterans and their families. Trump has promoted the Army's anniversary as a reason to hold a military parade in Washington, D.C., on Saturday, which is also his 79th birthday. Trump, who sees the military as a critical tool for domestic goals, has used the recent protests in Los Angeles as an opportunity to deploy the National Guard and U.S. Marines to quell disturbances that began as protests over immigration raids.
Yahoo
an hour ago
- Yahoo
Why Trump turned against ‘gold standard' mRNA vaccines
President Trump's administration has slammed the brakes on development of messenger RNA (mRNA) vaccines, which proved their lifesaving potential during the COVID-19 pandemic but have come under increasing scrutiny among skeptics of mainstream science. The vaccines marked a breakthrough in medical technology, drastically reducing the timeline for development of targeted vaccines and even showing promise in cancer research. Trump called mRNA the 'gold standard' when he rolled out the first COVID-19 vaccines. But now they are under assault by Trump's Health and Human Services (HHS) secretary, longtime anti-vaccine advocate Robert F. Kennedy Jr., and his allies in the 'make America healthy again' movement. HHS in late May canceled $766 million awarded to Moderna through the Biomedical Advanced Research and Development Authority (BARDA) to develop a potential mRNA vaccine for bird flu. HHS spokesperson Andrew Nixon said of the decision, 'This is not simply about efficacy — it's about safety, integrity, and trust.' 'The reality is that mRNA technology remains under-tested, and we are not going to spend taxpayer dollars repeating the mistakes of the last administration, which concealed legitimate safety concerns from the public,' he added. Unlike traditional vaccines that contain fragments or weakened versions of a virus, mRNA vaccines send messenger ribonucleic acid into cells to teach the immune system to recognize proteins connected to virus cells. According to Joseph Varon, president and chief medical officer of the Independent Medical Alliance (IMA), the concerns for mRNA vaccine skeptics are the expedited timeline and conditions in which the COVID-19 vaccine was approved. 'The biggest concern is that this rushed treatment still remains in use, even under an Emergency Use Authorization in some cases. It needs to be sent back through proper studies and vetting,' Varon told The Hill. 'There needs to be an established database of vaccine injuries that can be accurately quantified with full transparency, without politics or big money pressure influencing the data,' he added. 'There's a growing body of peer-reviewed studies that indicate the spike proteins are causing havoc in certain recipients.' The IMA, previously known as Front Line COVID-19 Critical Care Alliance, launched a campaign in support of Kennedy's nomination to be HHS secretary. The group drew controversy when its founders promoted ivermectin as a 'miracle drug' for COVID-19. Myocarditis, or inflammation of the heart muscle, is of particular concern among mRNA vaccine opponents. An analysis published in 2022 found that myocarditis occurred in about 31.2 cases per 1 million second doses of the Moderna COVID-19 vaccine, or 0.003 percent. Rates of myocarditis are significantly higher among people with COVID-19 infections than immunizations, however. The development of the COVID-19 mRNA vaccine was aided by the Trump administration's Operation Warp Speed, something Trump has boasted about at numerous points. In remarks in December 2020, the same month the first COVID-19 vaccines were deployed, Trump praised Operation Warp Speed's ability to develop a SARS-CoV-2 vaccine at a 'breakneck speed,' adding 'the gold standard vaccine has been done in less than nine months.' Though research on mRNA and its potential uses has been ongoing for decades, use of the vaccines in humans is relatively new. The first mRNA vaccine candidate tested in humans was for rabies in 2013, but it wouldn't be until the COVID-19 pandemic in 2020 that this technology would achieve commercial viability and widespread use. To Kennedy, this is too much of a coincidence. In his book 'The Wuhan Cover-Up: And the Terrifying Bioweapons Arms Race,' published in 2023, Kennedy suggests it was more than just happenstance that allowed for the deployment of Moderna's mRNA technology to coincide with the global pandemic. He pointed to a meeting attended by Dr. Anthony Fauci and former BARDA Director Rick Bright in which the officials met with virologists months before the COVID-19 pandemic broke out. The fact that attendees discussed the need for innovation in influenza research and vaccines became a point of conspiracy online. Kennedy noted that Bright called for something 'completely disruptive, that's not beholden to bureaucratic strings and processes,' writing, '[Bright] hinted that only a global crisis — like a pandemic — could induce government and industry to commit the billions of dollars necessary to create a new generation of 'plug-and-play' mRNA vaccines.' In the conversation Kennedy references, Bright was discussing the challenges of making influenza research 'sexy' for Ph.D. and postdoctoral students, surmising that something 'completely disruptive' would be needed to incite excitement in the field. Proponents of the mRNA technology point to its deployment in the COVID-19 pandemic and its role in reducing transmission as evidence of safety and efficacy. 'In the U.S., you know, we have a lot of real-world experience now with huge numbers of doses given. We have been following for significant or serious adverse events for a long time, and the rate of those serious adverse events is on par with what we see for other vaccines,' E. John Wherry, director of the Institute for Immunology and Immune Health at the University of Pennsylvania, said of mRNA vaccines. As Wherry notes, all vaccines have adverse side effects, but their safety compared with the diseases they inoculate against is 'incontrovertible.' And while critics take issue with the speed at which mRNA vaccines are developed, Wherry said this difference is precisely what sets these shots apart from older generations. 'mRNA vaccines have a couple of key benefits or features that really stand out compared to other vaccine platforms. One, they can be generated very, very quickly. So, you can adapt to changes very rapidly. This is much easier with an mRNA vaccine, where the COVID strain or flu strain mutates and changes from year to year,' Wherry said. 'The second is that it's relatively simple. So, we don't have to worry about, you know, impurities in, you know, an egg-grown vaccine or a cell-based grown vaccine synthesizing mRNA. There are very few components that go into it, and it can be synthesized with high purity.' Such mRNA vaccines are also potentially applicable for numerous conditions or even multiple different strains of the same virus, giving it more flexibility than traditional vaccinations. 'So, there are substantial benefits in flexibility, in speed, in simplicity of manufacturing and that probably also affects the cost of goods at the end of the day, which is perhaps a last advantage,' Wherry added. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.